daratumumab + N-(2-hydroxypropyl)methacrylamide copolymer + monomethyl auristatin E

**Daratumumab + N-(2-hydroxypropyl)methacrylamide copolymer + monomethyl auristatin E** is an experimental CD38-targeted antibody-polymer-drug conjugate nanomedicine developed for relapsed or refractory B-cell non-Hodgkin lymphoma. The construct covalently combines the anti-CD38 monoclonal antibody daratumumab with an HPMA-based copolymer scaffold carrying monomethyl auristatin E through a lysosomally cleavable valine-citrulline-para-aminobenzyl carbamate linker. Daratumumab directs the conjugate to CD38-positive lymphoma cells and promotes cellular internalization; intracellular linker cleavage releases MMAE, which inhibits tubulin polymerization and causes mitotic arrest and apoptosis. The HPMA polymer architecture is intended to enable a higher drug-to-antibody ratio than a conventional antibody-drug conjugate while maintaining antibody conjugation characteristics.